Two-year clinical outcome from the Iberian registry patients after left atrial appendage closure
Open Access
Abstract
Aims: The aim of this study was to observe the percentage of thromboembolic and haemorrhagic events over a 2-year follow-up in patients with non-valvular atrial fibrillation (NVAF) undergoing closure of the left atrial appendage (LAA) with an occlusion device. Observed events and CHADS2 (congestive heart failure, hypertension, age, diabetes, stroke history), CHA2DS2-VASc (also adding: vascular disease and sex) and HAS-BLED (hypertension, abnormal liver/renal function, stroke history, bleeding predisposition, labile international normalised ratios, elderly, drugs/alcohol use)-predicted events were compared. Methods: LAA closure with an occlusion device was performed in 167 NVAF patients contraindicated for oral anticoagulants and recruited from 12 hospitals between 2009 and 2013. At least two transoesophageal echocardiograms were performed in the first 6 months postimplantation. Antithrombotics included clopidogrel and aspirin. Patients were monitored for death, stroke, major and relevant bleeding and hospitalisation for concomitant conditions. Mean age was 74.68±8.58, median follow-up was 24 months, 5.38% had intraoperative complications and implantation was successful in 94.6% of subjects. Mortality during follow-up was 10.8%, mostly (9.5%) non-cardiac related. Bleeding occurred in 10.1% of subjects, 5.7% major and 4.4% minor though relevant, and 4.4% suffered stroke. Major bleeding and stroke/transient ischaemic attack events within 2 years (annual event rates, 290 patients/year) were less frequent than expected from CHADS2 (2.4% vs 9.6%), CHA2DS2-VASc (2.4% vs 8.3%) and HAS-BLED (3.1% vs 6.6%) risk scores (p<0.001, p=0.003, p=0.047, respectively). Conclusions: LAA closure with an occlusion device in patients contraindicated for oral anticoagulants is a therapeutic option associated with fewer thromboembolic and haemorrhagic events than expected from risk scores, particularly in the second year postimplantation.Keywords
This publication has 30 references indexed in Scilit:
- Warfarin Use and Stroke Risk Among Patients With Nonvalvular Atrial Fibrillation in a Large Managed Care PopulationClinical Therapeutics, 2013
- Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial FibrillationJACC, 2013
- The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapyEuropean Heart Journal, 2012
- Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort studyEuropean Heart Journal, 2012
- Standardized Endpoint Definitions for Transcatheter Aortic Valve Implantation Clinical TrialsJACC, 2011
- Left atrial appendage closure with amplatzer cardiac plug in atrial fibrillation: Initial european experienceCatheterization and Cardiovascular Interventions, 2010
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patientsJournal of Thrombosis and Haemostasis, 2009
- Effect of Clopidogrel Added to Aspirin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Bleeding complications in patients on anticoagulants who would have been disqualified for clinical trialsThrombosis and Haemostasis, 2008
- Selecting Patients With Atrial Fibrillation for AnticoagulationCirculation, 2004